.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Express Scripts
Covington
McKinsey
Julphar
Deloitte
Farmers Insurance
Citi
Fish and Richardson
Colorcon

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,645,988

« Back to Dashboard

Details for Patent: 5,645,988

Title: Methods of identifying drugs with selective effects against cancer cells
Abstract:The present invention involves a method of identifying drugs which selectively inhibit the growth of particular cancer cells, which method comprises: (a) contacting with the drug at least two cancer cells derived from the same type of biological material, wherein the cancer cells differ as to the presence of a particular DNA sequence, (b) measuring the effect of the drug on the growth of the cancer cells, and (c) determining whether there is a correlation between the effect of the drug on the cancer cells and the presence or absence of the DNA sequence in the cancer cells. The present invention further involves the use of such drugs.
Inventor(s): Vande Woude; George F. (Berryville, VA), Koo; Han-Mo (Gaithersburg, MD), Monks; Anne (Clarksburg, MD)
Assignee: The United States of America as represented by the Department of Health (Washington, DC)
Filing Date:Jun 15, 1994
Application Number:08/260,515
Claims:1. A method of identifying a drug which selectively inhibits the growth of a particular type of cancer cell, which method comprises:

(a) contacting with said drug at least two cancer cells derived from the same type of biological material, wherein said cancer cells differ as to the presence of a particular DNA sequence that was acquired in vivo,

(b) measuring the effect of said drug on the growth of said cancer cells, and

(c) determining whether there is a correlation between the effect of said drug on said cancer cells and the presence or absence of said DNA sequence in said cancer cells.

2. The method of claim 1, wherein said DNA sequence comprises an oncogenic tumor suppressor gene.

3. The method of claim 1, wherein said DNA sequence comprises an activated oncogene.

4. The method of claim 3, wherein said DNA sequence comprises an activated ras oncogene.

5. The method of claim 4, wherein said ras oncogene is K-ras-2.

6. The method of claim 5, wherein said K-ras-2 oncogene has been activated by a mutation in the 12th, 13th or 61st codon.

7. The method of claim 1, wherein said cancer cells are non-small cell lung cancer cells and wherein said DNA sequence comprises an activated oncogene or an oncogenic tumor suppressor gene.

8. The method of claim 7, wherein said DNA sequence comprises an activated oncogene.

9. The method of claim 8, wherein said DNA sequence comprises an activated ras oncogene.

10. The method of claim 9, wherein said ras oncogene is K-ras-2.

11. The method of claim 10, wherein said K-ras-2 oncogene has been activated by a mutation in the 12th, 13th or 61st codon.

12. The method of claim 1, wherein said cancer cell are colon cancer cells and wherein said DNA sequence comprises an activated oncogene or an oncogenic tumor suppressor gene.

13. The method of claim 12, wherein said DNA sequence comprises an activated oncogene.

14. The method of claim 13, wherein said DNA sequence comprises an activated ras oncogene.

15. The method of claim 14, wherein said ras oncogene is K-ras-2.

16. The method of claim 15, wherein said K-ras-2 oncogene has been activated by a mutation in the 12th, 13th or 61st codon.

17. The method of claim 1, wherein said cancer cells derived from the same type of biological material are obtained from different patients.

18. The method of claim 1, wherein said method comprises contacting with said drug more than two cancer cells derived from the same type of biological material.

19. The method of claim 1, wherein said cancer cells derived from the same type of biological material are obtained from the same patient.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Mallinckrodt
Accenture
Merck
Cerilliant
Deloitte
McKinsey
Colorcon
UBS
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot